Genetic Testing for Hereditary Breast, Ovarian, Pancreatic and Prostate Cancer - Medicare Advantage (Revised)
Act
by Sep 2, 2025
Effective date
Sep 2, 2025
Identified
Jun 24, 2026
Summary
Humana Medicare Advantage has updated their genetic testing policy for hereditary breast, ovarian, pancreatic and prostate cancer effective September 2, 2025. The policy establishes coverage criteria following CMS guidelines and MolDX requirements for molecular diagnostic tests and laboratory-developed tests.
Get alerts when payers change rules like this one
We check Humana and other payers every day and email you when a change matches your specialty and state.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.